Susan Sabo-Wagner, MSN, RN, OCN, of the American Oncology Network, expressed excitement toward networking, innovative discussions, and panels on patient advocacy at Patient-Centered Oncology Care® (PCOC) 2024.
Patient-Centered Oncology Care® (PCOC) 2024 will take place in Nashville, Tennessee, from September 12 to 13. The meeting will showcase experts in the oncology space with discussions surrounding recent innovations that target patient care to increase quality of life.
Susan Sabo-Wagner, MSN, RN, OCN, vice president of clinical innovation at the American Oncology Network, serves as cochair for PCOC this year. In this interview, she explains why she is looking forward to networking and the panels on patient advocacy.
This transcript has been lightly edited for clarity.
Transcript
What are you looking forward to most as cochair of PCOC this year?
The things that I'm most looking forward to is, number one, networking. I think PCOC really brings [together] quite a large group of very interesting people across the oncology spectrum. I love to get together to see everybody that comes to that. I think there's a lot of very interesting speakers this year, from the keynote to all of the different panels.
I was actually just taking a look at the agenda this morning, and I'm very interested in some of the innovation discussions and a lot of the specific discussions on that. Then I saw that there's a couple of prizes, so I think that's a really cool addition this year.
What panels or specific topics are you looking forward to being discussed at PCOC?
I think anything around patient-specific advocacy. There's a couple of different panels dedicated to the different aggregating organizations, and I think that's going to be very interesting to understand. And I think just kind of getting to know what everybody's doing in this space. There's been a lot of changes and reimbursement changes this year, so understanding how everyone is impacted and how they're making changes to face those.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More